FOR 2240: (Lymph)Angiogenesis And Cellular Immunity In Inflammatory Diseases Of The Eye

致盲性眼病通常与年龄有关，并且通常伴有异常炎症过程，这些炎症过程与病理性（淋巴）血管生成有关。本研究单位的目标是1.更好地了解眼部炎症性疾病的发病机制; 2.在此基础上，开发新的治疗概念，通过靶向异常（淋巴）血管生成和细胞免疫间接调节炎症过程来预防失明。2240研究单元更新的总体目标是：1.延长第一个资助期（2015-2018年）的已充分运行的项目; 2.增加两个新项目，及时更新FOR 2240的总体主题（“角膜缘干细胞在角膜淋巴管生成特权中的作用”和“淋巴和血管生成接种物抗宿主病”），3.将年轻和女性科学家以及相关领域（OCTimaging，UV诱导的DNA损伤，GvHD）的知名专家添加到PI/Coapplicantsand 4组中。进一步加强FOR 2240项目之间已经在进行的协同合作。在主题上，作为对第一个资助期开放问题的补充，我们的概念是更好地了解各种威胁视力、免疫介导、炎症和年龄相关性眼病的发病机制，包括年龄相关性黄斑变性（AMD）、干眼病、角膜移植排斥、葡萄膜炎和眼部肿瘤，特别关注病理性眼部（淋巴）血管生成和细胞免疫失调的机制作用。我们的进步的一个标志，也证明了我们已经做了相关的研究的承诺是4专利申请，已提交的第一个资助期由FOR PI。我们希望在成功的基础上继续努力，在更好地理解这些疾病的关键免疫和血管事件的基础上，在开发新的治疗概念方面取得重大进展。

Blinding diseases of the eye are often age-related and usuallyaccompanied by aberrant inflammatory processes which areassociated with pathological (lymph)angiogenesis. The aim of thisResearch Unit is 1. to better understand the pathogenesis ofinflammatory diseases of the eye and 2. based on that, to developnovel therapeutic concepts to prevent blindness based on indirectmodulation of inflammatory processes via targeting aberrant(lymph)angiogenesis and cellular imunity. The overall objectives ofthis renewal of Research Unit FOR 2240 are: 1. to extend thesuccessfully running projects of the first funding period (2015-2018),2. to add two new projects with timely new aspects of the overalltheme of the FOR 2240 (“role of limbal stem cells in corneallymphangiogenic privilege” and “lymph- and hemangiogenesis inocular graft-versus-host disease”), 3. to add young and femalescientists as well as established experts from associated areas (OCTimaging, UV-induced DNA damage, GvHD) to the group of PIs/Coapplicantsand 4. to further intensify the already ongoing synergisticcooperations between the FOR 2240 projects. Thematically,complementing the open questions from the first funding period, ourconcept is to better understand the pathogenesis of a diverse group ofsight-threatening, immune-mediated, inflammatory and age-relatedeye diseases, including age-related macular degeneration (AMD), dryeye disease, corneal graft rejection, uveitis and ocular tumors, with aspecial focus on the mechanistic role of pathologic ocular(lymph)angiogenesis and dysregulated cellular immunity. One sign ofour progress that also demonstrates the commitment we have madeto do translationally relevant research are the 4 patent applicationsthat have been filed in the first funding period by FOR PIs. We want tobuild on our successes and continue our efforts to maketranslationally relevant progress in developing new therapeuticconcepts based on a better understanding of key immunological andvascular events in these diseases.